EYEN - Earnings call transcript Q2 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by. And welcome to the Eyenovia Second Quarter 2020 Earnings Call. [Operator Instructions] Please be advised that today’s conference is being recorded. [Operator Instructions] I will now hand the conference over to your speaker today, Alex Lobo. Please go ahead.

Alexander Lobo

to webcast. quarter welcome call earnings and audio and afternoon, Eyenovia's XXXX second conference Good today Dr. me With are Sean Ianchulev, Michael Eyenovia's Officer; President John Chief Commercial. Executive Officer Eyenovia's of Financial and Chief Officer; and Rowe, Vice Gandolfo, Eyenovia's Chief Medical release Earlier for financial XX, the a June results ended announcing this months issued afternoon, XXXX. Eyenovia press three to XXXX, press on release, everyone for the which XX-Q the Form be second well with as encourage We of as read today's quarter will filed report Eyenovia's quarterly SEC. quarterly and website release press will also Eyenovia's company's The on available report at be eyenovia.com.

impact trial to market regulatory key trials, the candidates, supply the advantages such our manufacturing, our maintain acceptance product results, anticipated ability company's not financial the timing for, and the ability approvals and design, particularly which of existing uncertainties associated product others of candidates, today call, the to and and except most on personnel, report of Ianchulev. our qualified approval. discussed and retain of Sean COVID-XX to after fluctuations uncertainty XX our given of SEC events product webcast Form our investigational In COVID-XX, discussing social filings. is conference be of addition, impacted information clinical Please also statements to and going under COVID-XX be risks annual the call is broadcast, utility implied accurate and capabilities enrollment, ability reference. over that differ our only operations that today's for will call for may candidates, on opportunity forward-looking risks cautionary required Private XX, conditions subsequent marketing securities the our conference due turn of need This commercialization, to, results to could property our for timing, are date undertakes of update market regarding months release the by statements XX-K this on certain potential the and as in Please related obligation Eyenovia for impacts FDA our statements. provisions cost, additional but be will submit Securities and obtain, as our degree products, including and candidates, law. to money call potential timely With recent there including caution adversely of note number conference subject estimates statements that contained risks, fund product forward-looking which by the market progress, or These at intellectual results this the product with clinical chain, Actual through to business. call, Reform XXXX. being the reflect note Harbor be of we call, a the and that I'd have company's of rate Eyenovia's applications and the website, our for distancing, press of forward-looking risk Safe continue of this and listeners revise applicable or a stated yet Act. to information or by like its next archived impacts Eyenovia's from future August to the receive least management resulting those to We strategies will develop that any contains including forward-looking initiation, date to during covered trials, Litigation and these concern, limited be Dr. attract and filings, and to COVID-XX, economic to potential and the by risks, live in making materially related our call is our candidates, implement circumstances the said, in potential statements on raise sensitive to and as this could no time to detailed

Sean Ianchulev

the also end forward for enrollment Phase of everyone earnings we recruitment were safety pandemic. welcome, maintaining our and we of conference Eyenovia's And We the CHAPERONE completing patient second Alex. successfully look continue the past ongoing quarter, initiative resumed our that you, quarter, and This XXXX swiftly quarter study second call. to advancing myopia. clinical despite during III to our the to process. progressive very Thank At strategic COVID-XX pleased

and in excited executing of U.S opportunities turned Over pipeline agreement to the what growing our past most towards also couple its one attention alliances. alongside pharmacologic years. we're and building believe of is supply late and very outside COVID-XX III to license coming our interest development China to pharmacologic payments ophthalmologic markets, our seeing With to for of for we and presbyopia. on Vision impacts of when In financial and presbyopia on eligible for to million U.S. the we studies Arctic subject for $XX.XX impacts China a focused with clinical the for plan advanced to operations, the years, myopia any large company of COVID-XX. has exclusive MicroLine transaction of recently, now and months our additional kind space. initiate application been XXXX, for well the of these and as this with some drug step Greater we our receive new market we're We're another submit payments took have MicroStat CHAPERONE the markets. just benefit months and III mydriasis agreement, partnerships Phase up positioned unlock South ophthalmic makes receive over anticipate the we III Korean to programs Arctic in technology, based our the the and immediate More major of aim the comes of we recently to markets. the potential commercialization monetizing that trials, we're subject Asian This Eyenovia, completed the opportunities in remaining in of work it for to our excited coming MicroPine Vision, MicroStat VISION Phase by us MicroLine global to and presbyopia any our with programs now MicroPine and and of Phase Phase initiated We the trial, III treatment to the royalty stage very the initiating the

would our Before discuss I highlight clinical we Vision. progress, Michael our to call over with the to to like Michael? agreements Arctic hand

Michael Rowe

Asia. our MicroLine and the with announced we development Korea of Yesterday, China and from market children developing South of greater exclusive partnership it's China company well into Sean. of a commercializing in MicroPine expands you, focused in and significantly myopia have agreement already Arctic Vision, therapies based there license are the prevent of innovative and doctors This for to ophthalmic of estimated of published and the commercialization hundreds on parents a products potential use atropine our their millions children. the clinical supporting region Many of worsening. myopic aware where evidence, these Thank that

$XX.XX payments the to we related development as various are payment, of research terms additional milestones, as as royalty in into estimate initiation are the Korea, on and an of comprised clinical reach development based costs. well well of dollars. regulatory the and China payments that Payments payments. These South many additional are in supplier the of benefit with for of ages Korea, we're the adults there eligible alternative receive Greater also presbyopia. a XX nearly China between Additionally, and XX from to Under million of treatment pharmaceutical as South the could upfront of of age who up including episodic agreement payments tens and approvals and millions Greater may as

net from MicroLine In of not certain products products Vision MicroPine subject on supplied pay or Arctic mid addition, has percentage to such to and single-digit adjustments. us, Vision Eyenovia us royalty Arctic purchase by agreed a will sales for

transaction will net Senju part commercial Pharmaceuticals, percentage Eyenovia in of mid are of of payments to Vision license we of markets Arctic of proceeds Pharmaceuticals a the we the China South These largest to of is our the help products some presbyopia progressive rights and Overall, to our reach supply example products a myopia from will previously good pay by the world. royalty with which agreement international As strategy reacquired these Greater our to double-digit grow this Korea. that Vision. the Arctic part of in agreement, payments and received Arctic believe our announced and and Senju Vision address further and distribution

also this objectives non-dilutive our Importantly, provides transaction capital, help the in to us which execution the could with further States. of United support

on Now, the like would our ongoing Sean provide back hand Sean? update an activities. clinical to I to call to

Sean Ianchulev

Thanks, Michael. our advancing OUS we with thrilled We're Arctic look and forward Vision activities. to to partner

Since we reduce microdosing team highlighted well to further I the the has U.S the our as like we programs therapeutics to Opteject, clinical Now to to of including generated benefits our data Opteject of touch being would the the our ability dispenser. support the that eye, many amount in R&D as delivered. upon preservatives some recent have introduced highlight

team qualified which be and associated with free blow lead delivered year more free containers equates R&D benefits XXX Opteject for some waste dosing, daily research preservative daily the use twice to Opteject deliver put To with can drop medication per drug into We're and evaluating completed medication. separate for currently use in approximately per patient this great could for single to Our preservative individually where packages XXX dispenser patients field medication. our can that whether report has approximately this year recently eliminate packaged the packages. multi something packages happy to plastic be every plastic perspective, to use significant in than

the topical happy preservative Opteject improving potential the footprint way in target very imagine incredible packaging. has as delivery. of to accuracy well can that single on as waste and this waste of eliminating environmental the unit lead compliance You We're and free the

that key ophthalmology, context or that The seen meter study it peer-reviewed reduce the found study to where ophthalmology journal COVID-XX mind just risk is diameter and This surfaces and patients Medical is of opinion investigators and around published in of of sterility unmet within the of to tantamount contaminate a prevention when to an room. In asymptomatically, study need the the indeed present has critical our of we patients American the It the where contamination JAMA clinical the leaders. one need is recent for optometry addition, pandemic be spread of the this one in to increased can of was sat. environmental COVID-XX risk the contamination in today. of contamination physician patient Association, potential offices. In examination that aware risks be reduce COVID-XX virus example partners been top examine for are across

As as of use patient the dilating with regard Opteject exposure this has result, a and clinicians the significant drops. the struggle contamination cross to with risk to generated interest related

not well unfortunately to medicine, case touches of needles time. contaminated of or that drops the couple the patients. patient dropper to administered is medicine medical we standard to While tips in approximately journal the things found One two bacterial medication a are that And across patient the not ocular eyedropper bottle the do bottle used the patients. injection like dropper. often bottles across uses, publishing is XX established but only commonly surface and of between were XX% potentially the even of introducing contaminated It home studies three peer-reviewed reuse these is the that clinical or lids routinely XX% after eye itself were contamination not or the personnel with study third-party time. eyedropper XX bottle by by nearly reused, thermometer just the This at patients, where

handling study by that for were of that the the journal approximately the dropper The open bacteria Science, the coming XX% eyelashes the eyedroppers and patients. second of eyelids found culture, user Visual similarly of in positive of Ophthalmology bacterial or touching the from indicating Investigative tested from published the or

the protruding spray contamination. and gravity as potential prone remote eyedropper's to Opteject non-contact protrusion a is non The delivery. for horizontal spray drip in the conjunctiva lids free delivery has tip, tip velocity while driven low Now, is which well designed touch as risking tip dispensation,

reducing I'm of to that to Opteject the interest hard packaging. possible. be solution to also a as in Opteject very has NDA vital product working our soon for reduce contamination, perfect not from also reality pleased available come risk as So because clinics, and the of that use single of waste physicians by the much post-COVID make while And this it patients, end surprising about MicroStat. this to year, say submit could of to the the is this we are

that were in recruitment who Let resumed with our in address the safety, continued clinical pleased me stage progress top of clinical have the Phase worked nearly progressive and second announce had June all ensure advance to remains to our which III our our pipeline. COVID-XX We U.S. the Despite recent in our we for sites myopia. we therapeutic quarter, in best-in-class patient externalities closely late Among of to CHAPERONE clinical priority. we've study

the report receive them MicroPine with previously monitoring remote to dispenser Our years were with of randomized all and through in monitor trial concentration the baseline via XX are continued enrollment that randomized, Throughout clinical Phase treatment the is CHAPERONE clinical to enroll the patients complete all all very age, XX to now reduction placebo. follow-up months. is swiftly are X and study enrolled Opteject working more study. set pause, efficacy of the sites primary of myopia. efficacy our randomized patients treatment, for pleased and topical We're on progress is CHAPERONE examining XXX the safety believe track and Subjects two that to in the proprietary we or previously to to who and total delivered children of from advance formulation to double-masked change our telemedicine than either a processes, III And micro endpoint refractive with of in to has between enrollment. error atropine we're continued uneventfully which and clinical progressive

pandemic. to safest ensure this the possible And clinical the participates of COVID trials. create continues in who for constantly our everybody course, to depend working Of that environment improvement on we the we're

NDA test for MicroStat continuing mydriasis. pharmacologic with our As our are develop R&D to around I mentioned we for in Opteject, the conjunction recent

be our towards Based you As million eye If the market product, the commercial and approved, two under Phase formulation submitting precision future patients and XX dispenser [ph], phenylephrine-tropicamide. exams we Mid working performed is approximately introducing physicians high MicroStat, in our III million and by the name our X Combi the and novel positive often our used drugs priming application two of plan remember, MIST-X NDA MicroStat MIST-X alone. marketing FDA our in trials, on each brand to US year we're would the diagnostic cataract XXXX. therapeutics. combination U.S which of These are end surgeries our to first Opteject on for together

related year, lens, we Finally, initiating Phase trials III the of this and X MicroLine hopefully presbyopia. X China. availability the is We VISION our causes which the hardening the the excited Presbyopia, anticipate remain ready the population non-preventable treatment the VISION pharmacologic for ocular situation. of this program patient since about relatively the which to both age to Though, like easy is estimated well now focus studies over and of rapidly enroll and over the of that the as on the turn results. said, With financial size will nearby of the to this loss John gradual on to people portion of million COVID-XX to depend I eye's would discuss course, in ability call target. significant a as the an XX objects, very U.S., affects XXX those in

John Gandolfo

Thank Sean. you,

months I for to June financial three like review XX, the ended would XXXX. Now results our

XXXX, second loss a or quarter of loss second quarter per a and expenses of million $X.XX XXXX, for of same the $X For a million to XXXX. compares compares $X.XX $X.X share, reported and XX.X%. period share And approximately in Research of the or approximately net approximately of second the for approximately to net million, the XXXX. quarter for $X.X million this this per $X.X of we totaled development decrease

million quarter the of $X.X XX.X%. the of of second with and expenses of decrease approximately Total compensation an represents approximately quarter in approximately $X.X This compared XXXX XXXX, were period operating general a expenses million X.X%. million million $XXX,XXX to for the were same XXXX. total stock For of for second the second operating administrative included quarter $X approximately of expenses of expense. expenses $X.X XXXX, Operating for compared approximately increase non-cash

first the quarter from Vision, remarks. the current of through call capital XX, that concludes least from cash received company for proceeds approximately received would to of our XXXX, well hand anticipate to our $XX.X That Sean payment some financial agreement the back provides Arctic June XXXX. of cash statements. at over as As exercises, was I end our company's resources, We as with the closing like the recent with the sufficient warrant million. balance upfront

Sean Ianchulev

not you, Thank our validate successes believe to demonstrate to approach. but We recent John. continue mission, our further to only that our commitment our therapeutic also

MicroLine our South Our potential in license Greater Korea for demonstrates agreement MicroPine the with and States of and tremendous our for Arctic development expands and commercial technology. beyond well and the the interest United commercialization China Vision

on by first VISION As of are Please We the initiate open to like we We XXXX. Our to very end our any NDA the concludes all our Matt to clinical MicroStat remarks. And and question to go Operator? MicroLine. COVID-XX, mission. impact we trials Kaplan submit ahead. partners our and III to continue our shareholders, is for Instructions] look ahead, team, with support That our excited plan executing Phase questions. appreciate the of from from prepared subject Thalmann. first [Operator Ladenburg would call now for

Matt Kaplan

Good for Hi. guys afternoon, questions. and thanks taking

Just process. on bit wanted an to the a NDA get update of little MicroStat

that I product. COVID-XX been step kind Have mentioned impacted at stability think by on NDA rate all the for filing? timing that the those your limiting there has have before the of of studies a pandemic, you've been and impact could the

Sean Ianchulev

answer and the is question answer Matt, quick you. materially. good thank -- The not

because end submit foresight doesn't also but to change. to we thankful this execute team well and could tracking we're think this the the the the point NDA at I And this pandemic. still internal and tracking that been, And the by year. our plans of very with had and during hope we're that prepare it We case to our have are that's partners

Matt Kaplan

potentially to by and approval with your in preparation call next thoughts middle of And respect second of and if of then commercializing for it, terms Very kind where Okay. are that, half? could what good. commercialization MicroStat you you are let's year, get

Sean Ianchulev

And Yes. that I Michael. turn to will

give think in have as as touch need clinicians, the technology sterile-friendly seems post-COVID say, as reality in provide, more just from the characteristics answer. and we some most for delivery. would our to this the I understand an the able be earlier enormous he design the such community, a inherent from in in informed to dispenser you we remote I much the seen delivery Opteject non interest want to who our mentioned for delivery we discussed, the of and of a discussion,

we've So by clinical would interest ones today the better inbound like in seen lot particularly a that of that are to sites, in have provide our order to that care. studies

realize so really on patients, make respect. is such reality a are clinicians And possible to really this this as team. and in sure a can the unmet the we as as that hands on because need COVID possible the product we're get help want that we to And increased. even into the of of We has everything it patients, soon sitting

it and clinician So I it please want in on my to to the own personally. we me patients, get comment definitely the to a my Michael see as of want giving out rest commercialization. practice, but this

Michael Rowe

that with alluding One doctors more they're across now eyedropper good speak be to limiting or why pleasure, thing bottles Matt, to finished were whatever the they going which prior important single see XX much reusing my number that of COVID to Sean is either of thing interesting expensive. that's our in may what day, while going us with the Mid wanted strategic was we the Yes, things out to second use, patients does doctors move post-COVID than price were world, And certainly wouldn't take give it during to and XX we that Combi or COVID, having and around more a round on to difference is we just from more they're to going each. go And new we to these of to were before. research you. we market was that a of expensive. become And using can the And consider actually thought one and we is eliminate doing ways currently to view that, possibility advantage that what they're of of currently cost is because of it between our that a is point technology using. turn

So the this. one of that's of out come that positives

start or account where we're In end located the product, -- looking actually third with just from small to group that who going that biggest with key other of quarter next doesn't see people be terms launch would product. are, and the like it about sample of are that accounts this or will we'll ophthalmic selling a year, product that move is The we'll the third out and your there forward drops a there. about require expecting And lots quarter practices of nice the patients. thing -- probably to we're start you dozen be traditional a pharmaceutical see things

then So how it's sure ordering, go move the know can the them have on on people all kind of often. that in, thing that next set that and and where the make introduction, can an product, to to service not to office do up you you use

anything So for answer I you? else can

Matt Kaplan

That's Yes, that's very great. helpful.

Michael Rowe

Good, Matt.

Matt Kaplan

If upfront the Arctic and $XX.XX that of or maybe other terms milestones, I first another incorporated for good. into with question provided that John how extending of your your you of I should in million we cash terms questions, is that think just couple And looks in 'XX? about might. in guess runway, deal. It guidance Congratulations the kind on quarter of the very

John Gandolfo

Yes.

very good So question.

require capital So previously short-term, we well the long-term. strategy as over stated, as our additional we execute will as to

with us current Arctic recently source some potential well transaction, Vision future strategic capital. hopefully as pursuing, the similar the other non-dilutive of that a AV transactions transaction as to announced we're instruction the and So provides

the that To we do minimize mentioned be of in as to our to opportunistic impact any we'll possible Arctic of to transactions look way the was optimistic. these strategic we're need equity million. the continuing we the So But capital, raise X-K, to in most in payment dilution. upfront pursue terms and deal, we're $X it order we'll and Vision efficient the extent in

expected of years. So the next to are over X the balance come milestones the to X

over definitely capital execute to the that strategy. needs, a our capital term shorter as long-term need us look have significantly So continue we'll but for will we to help

Matt Kaplan

that helpful. last are Okay. parallel, And on tandem? Sean. be MicroLine to Do III launch in That's continued this question you in mentioned to the track The you both to intend for very will VISION program, VISION they or run you more be trials Phase year. trials

Sean Ianchulev

Yes, think that's good answer on I don't I a question. can give you that. a clear

are the move very daily, hope to sites. trial We're And a We literally or trials the to months. we two almost have and move evaluating within than we sites the less month. going hope we of we're following few a results that and very as clinical one enroll to this within Because status all forward, with going have to fast efficient.

is trials, So those the of we're the in enrollment Clasby, results III a talking on VP who months. few three of has experience she X to she six lot trials. months and you to X and both a MIST MIST the remember and beautifully done ophthalmology as Operations, complete the both were Ginger space in of executed Phase get

in studies. of for quickly. execute very time, will parallel, be more slightly do a go, we're what going same or those safety their very completely way whether to best sense regardless But for what's environment. At this we sequential to paced the it's or fully fast in So really the which sequential patients makes

Matt Kaplan

thanks again, progress. on congrats Great. the and Well, Great.

Sean Ianchulev

Matt. Thank you,

Operator

you. Thank

Chen is question Yi H.C. Please from with Our go Wainwright. next ahead.

Blair Cohen

Blair Yi. is on Cohen Hi. This for

for any enrolling and of and Just have comment trial a far? you all the from you've of enrollment Are speed sites August sites? Could so couple CHAPERONE questions now in on that added July you us. new the seen

Sean Ianchulev

of much are activation. of sites pretty running the all and stages final in up or Yes,

know, they on we periodically are guidance you not give going the As update before many how we to were in can study. patients decided and that them

we all caveats meaningful I enrollment. to sites, that clinical we the we that third relevant wave our authorize I'm the we geographies think months have see or nine a really second do complete and wave a particularly in what's saying And clinical today for where again, patients next and that is to with exacerbation, if hopefully probably expect or certain the over obviously more or have so partners.

XX at So with internally even are forget, people. doing time the after think two in because another a with are or and put in at the doing the we a Ginger same Eyenovia smoothly time, time with company running it's same -- realize be would to we're doing months submission really with clinical very the on not -- fast where paced. machine we very thought to want breath really well holding The than is we enrollment while we we for tracking and execute better be only what in has same NDA don't and the still But machine hooking I we discontinue so let's situation in we operations to the we're that breath enroll Phase our and fast IIIs so presbyopia. We're few again. initiate also COVID. where in is again, have this the And

and very happy we're are think we well very CHAPERONE. with we're yes, So, doing where I

Blair Cohen

Okay, before Vision milestones the to And to of in end Arctic do deal, then great. regards receive you any XXXX? expect

Sean Ianchulev

Yes we do.

XXXX XXXX, Before the was end of or question? what the

Blair Cohen

Both.

Sean Ianchulev

we Well, expect milestone a end so do to before expect that. to before Maybe answer receive both receive questions. would of the it XXXX, we it

Blair Cohen

great. That's Thank Okay, me. it you. for

Sean Ianchulev

Thank you.

Blair Cohen

Sure.

Operator

you. Thank

Michael is go Our with National from next Securities. ahead. question Please Brcic

Michael Brcic

contractually money way there sort how details or can this prohibited follow-up like about to and question, that one. That about, publicly? my talk is ones? milestones Is Thank much Hi. talking I we're on disclose we're that it of you. these any what to And so just want but once last you are -- get wasn’t that into the closest

Sean Ianchulev

approvals licensing I you are regarding along see oriented regulatory other that of the deals drug and nature type things could typical, lines. what the tell but milestones would you those with approvals,

addition, does per allow give I this transaction the well. get reimbursed In us can't expenses of just you development But to the as for details unfortunately, milestone. some

Michael Brcic

is me which it you -- this I On way. understandable. that, most involve Do not other in totally MicroStat? or about you do deal, MicroStat, thoughts your international let Were noticed they or different AV No, put doesn't advanced interested one. that have

Sean Ianchulev

Michael, take that? to do you want

Michael Rowe

Yes. Yes.

take me that. Let

at and first. wanted larger in to that so number these presbyopia the is of the countries, market with because for the with population children If you and look places and especially MicroPine than United the States, they the to that larger, just two go opportunity even even are myopia impacted, the far opportunity were those of MicroLine way control

not For not exams, not MicroStat, the which that them myopia. epidemic in attractive. as of for is is really product the based same It's upon it's number a just the of league

Michael Brcic

Okay.

for Going MicroPine progress milestones in I are based back But they the to Asia? on MicroLine, and are much and here milestones progress can based your there's the on you talk U.S., not or in about. the know the

John Gandolfo

those based progress primarily drugs in upon They’re Asia about Asia.

Sean Ianchulev

I think, the John, of are based here. we development though some say, upon would ones our probably actions

John Gandolfo

about Yes. license fee Yes. only talking I milestones, the was but correct.

Sean Ianchulev

Yes. Right.

both. So

Michael Brcic

well? with Europe Okay. had I as about in you Have market, -- but I this have you talks should speak know anyone

Sean Ianchulev

Yes.

we I months that results our fair say We wanted And nine very in and because as this to now. is on So very let the now is tremendous pipeline first time before, is U.S. recently Combi, our Again, opportunity III fact, and licensing. we spoken answer really And, interest. almost and to get reported Mid going first been it's our of which and me was to on six ago, for investing Eyenovia think spending really MicroStat, inbound where saw clear, focused we've this. we've the after things pike of be positive were we probably biggest Phase to and busy we partnering only started here,

so that. actually really small for big that through see company was distracting it So a very was it to

products So that Arctic deal first Vision. of the one I think our of is with

our easier think Asia. for we I markets We're and working the programs us Europe, attention respect effort. Michael more in for earlier we more here. spending that because are heading underway mentioned we going our other to should John of and are would the that and our mature as even Europe, owns come, Eyenovia we lot right they we effort, start especially Phase a really with III all more see markets have BD like are the within to scope. now probably that we're as it's in Obviously, turning And as trials

let we lot because So we're and But very terms we when out see Vision never came particularly expertise how that say me but in of selecting Arctic as I in they of partners, can said, who, interest extremely have lot to collaborating Asia, terms more on we where that think predict we're of and a diligent you're a different from going happy with hopefully, and in seen partnership. top entities. are, we

the You that right in partners want select to market.

And And interest think have through are so a that start that came we’re -- to we of in licensing inbound us. we that right going and partners of more process. our and feeding we diligence with through all the lot collaborating doing

Michael Brcic

Great.

and You been for my guys great. have been clients good very it's

thank it. Appreciate you. So

John Gandolfo

you. Thank

Operator

go with Thank ahead. you. [Operator Len Partners. Instructions] Our question from next is Please Stoc*Doc Yaffe

Leonard Yaffe

quick questions of much. very a Had couple for guys. you you Thank

VISION study for complete? First is III that to Phase should take long MicroLine. on How the

Sean Ianchulev

So a may X actually Phase X again, confused sorry the clear, have it's Yes. II you. a III not Phase we study, if to studies. just VISION VISION study, It's be I'm and but

think again. trials, that III X don't as the program, -- and they're Phase you VISION two I end a it program. in So, Phase sequential results VISION X program we you talked to at And III with Phase want by to look because entire complete part that the parallel, hope year, it's because initiate hope if same not complete a get, and this for bit the to the about we whole talk the let's probably -- the and they’re already little we’re program program, whole mid that of identical from program it about to need program of sometime year. year the that But III we about you next if

we I'm program. are exactly still it's sites resurgence, multiple extremely with having that planning expect where to some and all to got are again, These reality trials pandemic before feedback. know which are not we saying team a we've resurgence we we and everything and how we times, any already and fast closure that I think has else. readiness So the we complete that we And again, the have executed expect quickly an and a caveats paced and time, and But are quickly. in quickly, having not of enroll

We initiate we've has have people in the really by And that the that seen phenomenal It's for hope hardware, Michael with charts the groundbreaking a opportunities it's presbyopia off a our treating to that the research use. we market approach. far and the because protocol to ready, conducted. promptly that response first time pharmacologic spectacles means eliminate

we'll gone is have this furious. with over with it's externalities coming and keep some situation, you not COVID Hopefully updated. fast So and coming we'll trip a and soon

Leonard Yaffe

Great.

some now you last projection could In QX that end the advantages agreements terms licensing if 'XX And upfront Arctic as Opteject comment wondering your companies seeing year. there drug the first a in possible the you and and Opteject several to that licensing receive it that of from there from system as quarter Opteject any cash within companies I be Vision probably XXXX, of of not $X million. may should own include you what any agents. out your incorporate may of interest with ophthalmic of to for believe be incorporate exited that the the cash I would you the pharmacological Could delivery the being quarter mentioned a both licensing additional benefit through, to opposed between was that capability? of Does the given to are technology there delivery fact able addition their as in drug companies countries

Sean Ianchulev

Yes.

we that COVID then perfect every side make I topical needle it the the with question John talked and which pretty is one, start is much how mean make overdosed So every all obviously answer like logic, we I first currently inaccurately better. but that can. and last you're and about, your can drug -- on and threading delivered can can the let benefits your we've and me effects

we And ophthalmology, and selling unfortunately, ever don't oncology and pandemic. mean, in development very have the But epidemic in do and the for have at back established actually have -- progressive we up was other will a I in involved not we as with think spaces. same progressive of elongation some call strategic U.S I've seen pipeline we and vibrant do I laser the in impact data, be as in in especially and what successful have reprioritize the waking myopia are first patients a months, still before. focused on actually after Phase of the drugs dollar disease. a it III for injecting especially the I LUCENTIS. we've back huge almost, the can multibillion pathology, seen them market, the we is opportunity we and our the of to We're after mentioned been made MicroPine companies myopia, of space we technologies recent in interest And eye think eye topical and it which of the eyes again, I of the I treatment which we've people behind tremendous collateral retinal that. as here we

is easily. so everything going with for very the cautious. reviews discussions core to not through with real to right assets going obviously are the opportunity, we very and It us. These Board We and the deal part right internally and forth. course, them Of be has

programs about. opportunity the consider we're everything will But comes, But that an Arctic is happened obviously, cookie right bar was the the additional us, some not we all expected we either and and or on from motivated. they're very want on it. core yes, sure was that partnerships, we We a distracting happy fast with make clinical right because other we'll about and in Phase our the III news the still of programs, or the mission ever And happens. This the our very NDA, if our were candy all for hand opportunity the was that trial good executing on of not jar definitely milestones transaction ever to consider it us pretty So now milestone it have else. because in we if we and or teams -- see trials. Vision our what talked

on out started we've just So focusing have thought financially. will as operationally, everything said, and to I be that. strategically And

pipeline anybody phones? have see I And Now one Because we and use. that Opteject not future, were think eyedropper loaded like a we day we somebody smoothly more hope would an a becomes very we'll when would would as the see I there more this would to that why phone hopefully a sure I you and would see that that technology the and standard said, Opteject of of rotary we've dispenser. mobile internal of too perspective, use is imagine not I'm anybody we will hope executing use today guys phone from when want in an have somewhere hopefully why rotary I you care.

Leonard Yaffe

companies the myopia? rotary because My phone in couple companies, could on sense on avocado great that with lastly -- is the Yes. a position you of What wondering market progressive the is, the in guys for and other colored have was going what's competitive still other hangs I are discuss wall. on you atropine working

Sean Ianchulev

companies. huge big opportunity of their and need of some today. is have ahead are atropine. They market. basically probably private huge Taiwan losing using the it's else, our children now, kids the a just are It's like mean, This the this that all there a sight. of everybody I getting unmet XX% the is Asia, kids myopic. us of is are our kids This XX% all a because are countries that paradigm atropine on are a in like of right realized I and In They're same that think modification myopia. Yes. progressive eyedropper couple of formulation

this therapeutic the of in disease. XX% the of the So studies, for opportunity treatment of almost In we’ve an progressive we've myopia. seen amazing inflect progression reduction some index to

So I think it's are no going multiple there. wonder that players

patients the of with patients eye and put study adult with the time the XX% studies and they it almost in miss an seen pediatric I miss they kids about cannot now and of or are patients that adult have actual and drop, we've the that. importantly, is think these the are CHAPERONE tell in their their eyedropper If that eye we've cannot And can seen of MicroPine patients. patients. for of self eye what administering what in, more you Now our number the half shown that more clinical put

the drops. Just eye Their like it. iPhone love are putting not their they they're using and parents

is systemic minimize population anticholinergic just where highlights eyedropper would comes microdose. of number that down you with use and when an have why absorption, that to of want out again, particularly you I when anybody you're So absorption there, when any in have it drug Opteject that an to with a in a an cannot dispenser, would future, treatment companies a see the systemic microdose that of if can which atropine, giving have you why options you topical

atropine. good, So think, we down we And and think are there, delivery. very come I to multiple looking to horizon for there will outlook a are all when players it

Leonard Yaffe

either children close pandemic Yes, that much spending with the tragic consequences outdoors or may greater are in incidence not be that I'll indoors, sunshine. amount the computers because a just looking the this an of the disease, at time of comment of increase being of and of in one just iPhones

may well? unfortunately increase the of as it disease the So incidence

Sean Ianchulev

screen what talked actually the been Len, few about progressive myopia you're epidemiologic during have shown the we just and XX% much to saying a rate hour quantified thing call, your in an it in computer how actually has extra years, front it's last through our -- which additional And in Right. studies, increases of plus. last of

doing kids, how spend learning. many in the today, of remote computers additional including front my imagine own Now hours

the So escalated. to again, we're that of pandemic progressive make going to hugely going myopia see that -- epidemic is

see So At tripling today. byproduct have the the based of something over to great it's going learning persists, in problems the schools the the We're the more home And that unfortunate which we're last progressive already seeing rate to a time, to have is few doubling decades. we solution going even particularly myopia. it remote parents and stretches of this get complicating progress same if and to with eyeball now and you myopia, kids to back once their and your and go be. to unprogress. and shrink we patient why sclera and need you should where Once cannot product stretches progressive retina cannot patients we that's your it think to back early because you their and

it's think really to most as major at again, you're need it's least top as quickly us dilating it's mind, we an the priorities. Why need And because asked, going as to possible and the about get it's those I this -- biggest much for a very happy important important to the thing somebody think to are and here and our asks progressive only Well, in think of an at And that's So execute more beginning. doing aren't Arctic you do, unmet fast global keep the markets they Asia one myopia. I disease I bigger and and you particularly a drops? important and of now where in to attention much spend Vision. for epidemic, capital China your

Leonard Yaffe

much. so Thanks Great.

Sean Ianchulev

welcome. You're

Operator

National a Thank with follow-up you. Securities. And go have from ahead. Brcic Please Michael we

Michael Brcic

that still have for about to if over work? through they the they go this a have droppers? So to of even about Obviously, -- technology is question. how and approved, Or your delivery licensing would are Opteject want they sort opposed system. Hi. as the it's different Do What do thing, some that trials prescription to because with to drugs? counter adopt Yes. trial? What a drugs, your

Sean Ianchulev

Yes.

an And it's II, fast development clinical literally different. everything every product, is and go for really So established process this a but whether a a prescription technology Again, advantage Phase you of this time. very is Phase product, different, a paced simple great microdosing. because is validation indication through very I, it's it's to have don't for

and the for need counter, and simpler, to that tackle really means for prioritize some the about the needs us and -- our artificial other where, our easier. we biggest biggest tears like even we've actually I think the to And artificial prioritize and We schedule need talked time. same before at first. over it's schedule us, priorities For -- what opportunities tears unmet

the and Opteject. perfect I it's unmet the now for the needs. anti-redness think and focusing eye a But right dry on over-the-counter, bigger anti-itch all we're case for use of medications

to really differentiated in take the and completely product. is differentiate, invest the technology for programs they because and this undifferentiated is if over-the-counter literally can in strategic, and parallel it's big course, XX a Of begging hands of in market a

blaze course, we programs, X that of think and and in case, can faster satisfied them. in is a very where others, high but three And can late-stage are company, it Of others of company to very to that. I on many laser don't traded parallel, were the there focused we value. that publicly go doing for But small do that with after ophthalmology in are redirect we us we much we'll end programs that. we come a some and have now We're for runway even

Michael Brcic

Right.

the of one that? drugs are sorry Finally, you could there thought questions. eye? this, that other ballpark of about but this that those about be ophthalmologic through out Have Are delivered is the not

Sean Ianchulev

Yes, the would there of not eye. I for would intellectual And technology are. internal area and again, the opportunities again, to proprietary think of on also that looking But scope we that efforts the are used, want we're initially in and Opteject also of be we that. you not and have comment potentially deliver early necessarily information I in or be the have also property. could could and there some stages in at too, given some those

You deliver mouth, in tympanic can in potentially the membrane in or the the ear.

stream the the can what on come a precise a we're printing, We're technology. which lot print array droplets of micro So micro one very and a of in really applications doing, there's is inkjet surface, thinking even starting up patents and and all ophthalmology applications. the property with And now a that grow we’re beyond. lot so intellectual we have in about and as many of patents, we're we

It's question. it on something appreciate more about good R&D the we're very regardless. I thinking So side, but

Michael Brcic

very much Great. Thank you again.

Sean Ianchulev

Sure.

Operator

I Q&A his Thank you. remarks. for to for this turn would call concludes our final the Ianchulev back like session to Sean today. And

Sean Ianchulev

the today, And think detailed the productive we'll progress A time have was report. everybody and thank more reconvene when to Eyenovia we and on Again, all I call on to very we here getting III said interesting with questions. It's details you further a thank X:XX updates. I bearing East think programs, for Yes. for with late. for next And staying call, very want enough it I us now Phase happening next hope these earnings collaborations, multiple is lot markets. at multiple Coast.

So and with for you everybody, please tracking thank stay for us. safe

Operator

ladies that, gentlemen, thank in participating and with you program. we for And today's

You may disconnect. now

Eyenovia (EYEN) 12 Aug 202020 Q2 Earnings call transcript